Araştırma Makalesi
BibTex RIS Kaynak Göster

Evaluation of laboratory parameters in inflammatory myositis

Yıl 2021, Cilt: 12 Sayı: 3, 255 - 259, 29.09.2021
https://doi.org/10.18663/tjcl.947989

Öz

Aim: Polymyositis (PM) and dermatomyositis (DM) are the two most common forms of idiopathic inflammatory myositis (IIM) and they are generally rare diseases. We evaluate the relationship of C-reactive protein (CRP)/albumin ratio (CAR), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio and other inflammatory markers with IIM.
Material and Methods: 30 patients and 30 healthy volunteers aged >18 years were included. Demographic data such as age, gender were recorded. CRP, erythrocyte sedimentation rate (ESR), albumin values, leukocyte, neutrophil, lymphocyte, platelet counts were determined.
Results: The median (IQR) age of the patients and healthy volunteers were 46 (38-60) years and 45 (42-52) years, respectively. 50% of the patients had a diagnosis of DM and 50% of them had a diagnosis of PM, and the median (IQR) duration of disease was 4 (0.5-13) years. The median value of CAR was 3.6 (1.0-5.1) in the patient group and 0.3 (0.1-0.6) in the control group; the NLR was 3.4 (2.3-4.4) in the patient group, 1.8 (1.6-2.1) in the control group; PLR was 223 (157-249) in the patient group, 107 (100-125) in the control group and CAR, NLR, and PLR values between the groups were significantly different (p<0.001, p=0.002 and p=0.040, respectively).
Conclusion: CAR can be considered as a helpful assessment tool to show inflammation in patients with IIM.

Kaynakça

  • 1. Furst D.E., et al., Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve, 2012; 45: 676-83.
  • 2. Ha Y.J., et al., Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. PLoS One, 2018; 1: 0190411.
  • 3. Marie I., et al., Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol, 2001; 28: 2230-7.
  • 4. Airio A, H. Kautiainen, and M. Hakala, Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol, 2006; 25: 234-9.
  • 5. Benbassat, J., et al. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum, 1985; 28: 249-55.
  • 6. BOHAN, A., et al., A COMPUTER-ASSISTED ANALYSIS OF 153 PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS. Medicine, 1977; 56: 255-86.
  • 7. Carpenter, J.R., et al., Survival in polymyositis: corticosteroids and risk factors. J Rheumatol, 1977; 4: 207-14.
  • 8. DeVere, R. and W.G. Bradley. Polymyositis: its presentation, morbidity and mortality. Brain, 1975; 98: 637-66.
  • 9. Dankó, K., et al. Long-Term Survival of Patients With Idiopathic Inflammatory Myopathies According to Clinical Features: A Longitudinal Study of 162 Cases. Medicine, 2004; 83: 35-42.
  • 10. Henriksson, K.G. and P. Sandstedt .Polymyositis--treatment and prognosis. A study of 107 patients. Acta Neurol Scand, 1982; 65: 280-300.
  • 11. Hochberg, M.C., D. Lopez-Acuna, and A.M. Gittelsohn, Mortality from polymyositis and dermatomyositis in the United States, 1968-1978. Arthritis Rheum, 1983; 26: 1465-71.
  • 12. Lynn, S.J., et al., Adult-onset inflammatory myopathy: North Canterbury experience 1989–2001. Internal Medicine Journal, 2005; 35: 170-3.
  • 13. Mustafa, K.N. and S.S. Dahbour, Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol, 2010; 29: 1381-5.
  • 14. Schiopu, E., et al., Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Research & Therapy, 2012; 14: 22.
  • 15. Torres, C., et al., Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity, 2006; 39: 205-15.
  • 16. Yamasaki, Y., et al., Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol, 2011; 38: 1636-43.
  • 17. Yu, K.H., et al., Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol, 2011; 30: 1595-601.
  • 18. Uthman, I., D. Vázquez-Abad, and J.L. Senécal, Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum, 1996; 26: 447-58.
  • 19. Maugars, Y.M., et al., Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol, 1996; 14: 263-74.
  • 20. Marie, I., Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep, 2012; 14: 275-85.
  • 21. Dalakas, M.C., Inflammatory muscle diseases. N Engl J Med, 2015; 372: 1734-47.
  • 22. Salvador, F.B. and D.A. Isenberg, Outcome predictors in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol, 2012; 30: 980.
  • 23. Lu, X., Q. Peng, and G. Wang, Discovery of new biomarkers of idiopathic inflammatory myopathy. Clin Chim Acta, 2015; 444: 117-25.
  • 24. Templeton, A.J., et al., Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014; 106: 124.
  • 25. Xu, X.L., et al., A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma. PLoS One, 2015; 10: 0138657.
  • 26. Ishizuka, M., et al., Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer. Ann Surg Oncol, 2016; 23: 900-7.
  • 27. Rifaioglu, E.N., et al., Neutrophil to lymphocyte ratio in Behçet's disease as a marker of disease activity. Acta Dermatovenerol Alp Pannonica Adriat, 2014; 23: 65-7.
  • 28. Uslu, A.U., et al., Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis, 2015; 18: 731-5.
  • 29. Qin, B., et al., Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol, 2016; 26: 372-6.
  • 30. Peng, Y.F., et al., Platelet to Lymphocyte Ratio in Polymyositis as a Marker of Disease Activity. Clin Lab, 2016; 62; 915-9.
  • 31. Gao, M.Z., et al., Red blood cell distribution width and neutrophil to lymphocyte ratio are correlated with disease activity of dermatomyositis and polymyositis. J Clin Lab Anal, 2018; 32.
  • 32. Yang, W., et al., Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis. Clin Chim Acta, 2017; 465: 11-6.
  • 33. Medsger, T.A., Jr., H. Robinson, and A.T. Masi, Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum, 1971; 14: 249-58.
  • 34. Limaye, V., et al., Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J, 2012; 42: 191-8.
  • 35. Sunar, İ. and Ş. Ataman, Serum C-Reactive Protein/Albumin Ratio in Rheumatoid Arthritis and its Relationship With Disease Activity, Physical Function, and Quality of Life. 2020; 35: 247-53.
  • 36. Absenger, G., et al., A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer, 2013; 109: 395-400.
  • 37. Seringec Akkececi, N., et al., The C-Reactive Protein/Albumin Ratio and Complete Blood Count Parameters as Indicators of Disease Activity in Patients with Takayasu Arteritis. Med Sci Monit, 2019; 25: 1401- 09.
  • 38. Moon, J.S., et al., C-Reactive Protein to Serum Albumin Ratio Is an Independent Predictor of All-Cause Mortality in Patients with ANCA-Associated Vasculitis. 2018; 59: 865-71.

İnflamatuar miyozitte laboratuvar parametrelerinin değerlendirilmesi

Yıl 2021, Cilt: 12 Sayı: 3, 255 - 259, 29.09.2021
https://doi.org/10.18663/tjcl.947989

Öz

Amaç: Polimiyozit (PM) ve dermatomiyozit (DM), idiyopatik inflamatuar miyozitin (İİM) en sık görülen iki formudur ve genellikle nadir görülen hastalıklardır. C-reaktif protein (CRP)/albümin oranı (CAR), nötrofil/lenfosit oranı (NLR), trombosit/lenfosit oranı ve diğer inflamatuar belirteçlerin İİM ile ilişkisini değerlendirmeyi amaçladık.
Gereç ve Yöntemler: 18 yaş üstü, 30 hasta ve 30 sağlıklı gönüllü dahil edildi. Yaş, cinsiyet gibi demografik veriler kaydedildi. CRP, eritrosit sedimantasyon hızı (ESR), albümin değerleri, lökosit, nötrofil, lenfosit, trombosit sayıları belirlendi.
Bulgular: Hastaların ve sağlıklı gönüllülerin medyan (IQR) yaşı sırasıyla 46 (38-60) yıl ve 45 (42-52) yıl idi. Hastaların %50'sine DM, %50'sine PM tanısı konuldu ve ortanca (IQR) hastalık süresi 4 (0,5-13) yıldı. CAR medyan değeri hasta grubunda 3,6 (1,0-5,1) ve kontrol grubunda 0,3 (0,1-0,6); NLR hasta grubunda 3,4 (2,3-4,4), kontrol grubunda 1,8 (1,6-2,1) idi; Hasta grubunda PLR 223 (157-249), kontrol grubunda 107 (100-125) ve gruplar arasında CAR, NLR ve PLR değerleri anlamlı olarak farklıydı (sırasıyla, p<0,001, p=0,002 ve p=0,040).
Sonuç: CRP/albumin oranı, IIM'li hastalarda inflamasyonu göstermek için yararlı bir değerlendirme aracı olarak düşünülebilir.

Kaynakça

  • 1. Furst D.E., et al., Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve, 2012; 45: 676-83.
  • 2. Ha Y.J., et al., Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. PLoS One, 2018; 1: 0190411.
  • 3. Marie I., et al., Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol, 2001; 28: 2230-7.
  • 4. Airio A, H. Kautiainen, and M. Hakala, Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol, 2006; 25: 234-9.
  • 5. Benbassat, J., et al. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum, 1985; 28: 249-55.
  • 6. BOHAN, A., et al., A COMPUTER-ASSISTED ANALYSIS OF 153 PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS. Medicine, 1977; 56: 255-86.
  • 7. Carpenter, J.R., et al., Survival in polymyositis: corticosteroids and risk factors. J Rheumatol, 1977; 4: 207-14.
  • 8. DeVere, R. and W.G. Bradley. Polymyositis: its presentation, morbidity and mortality. Brain, 1975; 98: 637-66.
  • 9. Dankó, K., et al. Long-Term Survival of Patients With Idiopathic Inflammatory Myopathies According to Clinical Features: A Longitudinal Study of 162 Cases. Medicine, 2004; 83: 35-42.
  • 10. Henriksson, K.G. and P. Sandstedt .Polymyositis--treatment and prognosis. A study of 107 patients. Acta Neurol Scand, 1982; 65: 280-300.
  • 11. Hochberg, M.C., D. Lopez-Acuna, and A.M. Gittelsohn, Mortality from polymyositis and dermatomyositis in the United States, 1968-1978. Arthritis Rheum, 1983; 26: 1465-71.
  • 12. Lynn, S.J., et al., Adult-onset inflammatory myopathy: North Canterbury experience 1989–2001. Internal Medicine Journal, 2005; 35: 170-3.
  • 13. Mustafa, K.N. and S.S. Dahbour, Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol, 2010; 29: 1381-5.
  • 14. Schiopu, E., et al., Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Research & Therapy, 2012; 14: 22.
  • 15. Torres, C., et al., Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity, 2006; 39: 205-15.
  • 16. Yamasaki, Y., et al., Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol, 2011; 38: 1636-43.
  • 17. Yu, K.H., et al., Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol, 2011; 30: 1595-601.
  • 18. Uthman, I., D. Vázquez-Abad, and J.L. Senécal, Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum, 1996; 26: 447-58.
  • 19. Maugars, Y.M., et al., Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol, 1996; 14: 263-74.
  • 20. Marie, I., Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep, 2012; 14: 275-85.
  • 21. Dalakas, M.C., Inflammatory muscle diseases. N Engl J Med, 2015; 372: 1734-47.
  • 22. Salvador, F.B. and D.A. Isenberg, Outcome predictors in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol, 2012; 30: 980.
  • 23. Lu, X., Q. Peng, and G. Wang, Discovery of new biomarkers of idiopathic inflammatory myopathy. Clin Chim Acta, 2015; 444: 117-25.
  • 24. Templeton, A.J., et al., Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014; 106: 124.
  • 25. Xu, X.L., et al., A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma. PLoS One, 2015; 10: 0138657.
  • 26. Ishizuka, M., et al., Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer. Ann Surg Oncol, 2016; 23: 900-7.
  • 27. Rifaioglu, E.N., et al., Neutrophil to lymphocyte ratio in Behçet's disease as a marker of disease activity. Acta Dermatovenerol Alp Pannonica Adriat, 2014; 23: 65-7.
  • 28. Uslu, A.U., et al., Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis, 2015; 18: 731-5.
  • 29. Qin, B., et al., Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol, 2016; 26: 372-6.
  • 30. Peng, Y.F., et al., Platelet to Lymphocyte Ratio in Polymyositis as a Marker of Disease Activity. Clin Lab, 2016; 62; 915-9.
  • 31. Gao, M.Z., et al., Red blood cell distribution width and neutrophil to lymphocyte ratio are correlated with disease activity of dermatomyositis and polymyositis. J Clin Lab Anal, 2018; 32.
  • 32. Yang, W., et al., Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis. Clin Chim Acta, 2017; 465: 11-6.
  • 33. Medsger, T.A., Jr., H. Robinson, and A.T. Masi, Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum, 1971; 14: 249-58.
  • 34. Limaye, V., et al., Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J, 2012; 42: 191-8.
  • 35. Sunar, İ. and Ş. Ataman, Serum C-Reactive Protein/Albumin Ratio in Rheumatoid Arthritis and its Relationship With Disease Activity, Physical Function, and Quality of Life. 2020; 35: 247-53.
  • 36. Absenger, G., et al., A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer, 2013; 109: 395-400.
  • 37. Seringec Akkececi, N., et al., The C-Reactive Protein/Albumin Ratio and Complete Blood Count Parameters as Indicators of Disease Activity in Patients with Takayasu Arteritis. Med Sci Monit, 2019; 25: 1401- 09.
  • 38. Moon, J.S., et al., C-Reactive Protein to Serum Albumin Ratio Is an Independent Predictor of All-Cause Mortality in Patients with ANCA-Associated Vasculitis. 2018; 59: 865-71.
Toplam 38 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Özgün Makale
Yazarlar

Melih Pamukcu 0000-0002-9129-0503

Tuğba İzci Duran 0000-0003-4428-9873

Yayımlanma Tarihi 29 Eylül 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 12 Sayı: 3

Kaynak Göster

APA Pamukcu, M., & İzci Duran, T. (2021). Evaluation of laboratory parameters in inflammatory myositis. Turkish Journal of Clinics and Laboratory, 12(3), 255-259. https://doi.org/10.18663/tjcl.947989
AMA Pamukcu M, İzci Duran T. Evaluation of laboratory parameters in inflammatory myositis. TJCL. Eylül 2021;12(3):255-259. doi:10.18663/tjcl.947989
Chicago Pamukcu, Melih, ve Tuğba İzci Duran. “Evaluation of Laboratory Parameters in Inflammatory Myositis”. Turkish Journal of Clinics and Laboratory 12, sy. 3 (Eylül 2021): 255-59. https://doi.org/10.18663/tjcl.947989.
EndNote Pamukcu M, İzci Duran T (01 Eylül 2021) Evaluation of laboratory parameters in inflammatory myositis. Turkish Journal of Clinics and Laboratory 12 3 255–259.
IEEE M. Pamukcu ve T. İzci Duran, “Evaluation of laboratory parameters in inflammatory myositis”, TJCL, c. 12, sy. 3, ss. 255–259, 2021, doi: 10.18663/tjcl.947989.
ISNAD Pamukcu, Melih - İzci Duran, Tuğba. “Evaluation of Laboratory Parameters in Inflammatory Myositis”. Turkish Journal of Clinics and Laboratory 12/3 (Eylül 2021), 255-259. https://doi.org/10.18663/tjcl.947989.
JAMA Pamukcu M, İzci Duran T. Evaluation of laboratory parameters in inflammatory myositis. TJCL. 2021;12:255–259.
MLA Pamukcu, Melih ve Tuğba İzci Duran. “Evaluation of Laboratory Parameters in Inflammatory Myositis”. Turkish Journal of Clinics and Laboratory, c. 12, sy. 3, 2021, ss. 255-9, doi:10.18663/tjcl.947989.
Vancouver Pamukcu M, İzci Duran T. Evaluation of laboratory parameters in inflammatory myositis. TJCL. 2021;12(3):255-9.


e-ISSN: 2149-8296

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.